Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15517008 | 0.85 | LCK (0.55) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL204076 | 0.84 | GAA (0.48) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL18748566 | 0.81 | MAOA (0.44) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL27910086 | 0.81 | HMGCR (0.51) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL2479612 | 0.80 | HTT (0.46) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL28130717 | 0.80 | USP2 (0.39) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL10971731 | 0.79 | CYP3A4 (0.53) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL5838887 | 0.79 | CYP3A4 (0.58) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL10497610 | 0.79 | CYP3A4 (0.53) | CYP3A4MAPK1SMN1; SMN2USP2HTT | |
| SCHEMBL1203850 | 0.77 | ALDH1A1 (0.53) | CYP3A4MAPK1SMN1; SMN2USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| EP-0783505-B1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2001-03-07 | — | — | EP | disclosed |
| US-5869485-A | Pyrrolo 2,3-d!pyrimidines and their use | NOVARTIS FINANCE CORP. (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0783505-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | Novartis AG (CH) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010028-A1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | CYP3A4 906/4885MAPK1 2467/4885SMN1; SMN2 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.